Key result
Chronic post-stroke metformin promotes functional recovery and angioneurogenesis via glial AMPK activation.
Why the study?
Although epidemiologic evidence suggests that metformin reduces stroke incidence and severity, the underlying mechanisms remain unclear and experimental studies on acute stroke outcomes have reported controversial results.
How do the timing, duration, and cell-specific AMPK activation of metformin treatment affect acute infarct damage and long-term functional recovery in experimental stroke?
How do the timing, duration, and cell-specific AMPK activation of metformin treatment affect acute infarct damage and long-term functional recovery in experimental stroke?
Answers are grounded in this paper and cite their sources.
This review highlights that while acute pre-stroke metformin has complex, dose- and route-dependent effects on acute infarction, post-stroke chronic metformin consistently promotes long-term functional recovery and brain repair via AMPK-mediated angioneurogenesis and microglial polarization.
Increasing epidemiologic evidence suggests that metformin, a well-established AMPK activator and the most favorable first-line anti-diabetic drug, reduces stroke incidence and severity. However, the mechanism for this remains unclear. Moreover, previous experimental studies have reported controversial results about the effects of metformin on stroke outcomes during the acute phase. However, recent studies have consistently suggested that AMPK-mediated microglia/macrophage polarization and angioneurogenesis may play essential roles in metformin-promoted, long-term functional recovery following stroke. The present review summarizes the neuropharmacological actions of metformin in experimental stroke with an emphasis on the recent findings that the cell-specific effects and duration of AMPK activation are critical to the effects of metformin on stroke outcomes.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2015) conducted a review in Experimental stroke / cerebral ischemia. Metformin was evaluated on Acute cerebral infarction damage and long-term post-stroke functional recovery and angioneurogenesis. Metformin promotes long-term post-stroke functional recovery and angioneurogenesis via glial AMPK activation when given chronically after stroke, though acute pre-stroke effects vary by dose.
Synapse has enriched 10 related papers. Consider them for comparative context: